Tuesday March 8th 2022



MyCellHub welcomes Jacques Parlongue as CEO starting from today. Jacques brings his expertise and track record in managing successful international scale-ups, including growing ten-fold the company N-SIDE during his last assignment. MyCellHub is a modular data management and analysis (SaaS) platform that streamlines and automates complex workflows in the bio-manufacturing industry. It can count among its customers companies like eTheRNA immunotherapies, RD-Biotech, TRU Cleanroom Cleaning and EXO Biologics.

Process automation

MyCellHub’s platform is specifically designed for biotech and biopharma companies that are developing medicines. As soon as the research and development phase is completed, production is scaled up. Once in production, everything happens according to standardised processes in clean rooms or controlled laboratory environments and the process is subject to strict quality requirements. This results in quite a few administrative challenges, while it is precisely in this phase of life that bio-manufacturing companies need efficiency and automation.

MyCellhub is a great added value for companies with complex development or production workflows. The platform consists of two parts. On the one hand, there is a mobile application for the operators in the cleanroom or lab environment that supports them by means of interactive work instructions to carry out complex processes and reduce the risk of errors. In addition, there is an online data management application that centralises all processed data from the mobile app into a general overview that facilitates the planning and monitoring of workflows and processes.

Combining expertise, maximising impact

“We, the founders of MyCellHub and the Board of Directors, are very pleased to welcome Jacques on board. His expertise is a key addition, and in combination with the existing team, it further enhances our ambition”, says Toon Lambrechts, co-founder & Chief Business Development Officer MyCellHub.

“I am thankful to Simon Alexandre from the Faktory Fund for making the initial introduction! And thrilled to join MyCellHub at a critical stage, from a start-up to a scale-up, where my experience can be specifically leveraged. Combining the talents of the exceptional existing team with the experience I accumulated in SaaS and Life Science, will maximise the impact of our software platform” commented the new CEO.

Advanced Therapies Medicinal Products

Ief Leroy, Chairman of the Board MyCellHub explained: “The medical world is facing rapid changes and advanced therapies – such as cell and gene therapy as well as personalised medicine – are gaining considerable importance. And the innovation brought by the MyCellHub platform is one of the top solutions to address this challenge.”

“As a KU Leuven spin-off, the innovation quality level of MycellHub is already very high. Thanks to the recent additional funding round and support from the Limburg Investment Company LRM, The Faktory Fund, CoFoundry, Noshaq and Gemma Frisius Fund, we will bring it to the next level with new product innovations in usability and data analytics to be announced soon. Stay tuned!” concluded Jacques Parlongue.